drugset / Trial / NCT02393378
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of namilumab in combination with existing methotrexate (MTX) therapy over 24 weeks in participants with moderate to severe early rheumatoid arthritis (RA), diagnosed within 6 months and inadequately controlled by MTX alone.
Timeline
- Start
- 2015-04-08
- Primary completion
- 2016-06-27
- Completion
- 2016-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Comparator | Namilumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Background | Methotrexate | Small molecule | — | — |
| Background | folic acid | Other / unclassified | — | — |